Clinical trial
ZU-SkinSIT-001 Single Center Phase I/IIa, Placebo Controlled, Randomized, Double Blind Study to Assess the Clinical Efficacy and Safety of a Novel Method of Specific Allergen Immunotherapy in Grass Pollen Allergic Subjects by Epicutanous Allergen Administration
NCT00457444 is registered in ClinicalTrials.gov with University of Zurich as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- ZU-SkinSIT-001 Single Center Phase I/IIa, Placebo Controlled, Randomized, Double Blind Study to Assess the Clinical Efficacy and Safety of a Novel Method of Specific Allergen Immunotherapy in Grass Pollen Allergic Subjects by Epicutanous Allergen Administration
- Lead sponsor
- University of Zurich
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- December 31, 2005
- Completion date
- November 30, 2006
- Enrollment
- 35
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
rhinoconjunctivitis